{
    "clinical_study": {
        "@rank": "148195", 
        "brief_summary": {
            "textblock": "To assess the efficacy of Retrovir (AZT) therapy in the treatment of HIV Ab positive persons\n      with impairments in neuropsychological functioning. To assess the safety, virologic, and\n      immunologic effects of AZT therapy in HIV Ab positive persons with neuropsychological\n      impairment but minimal other symptomatology."
        }, 
        "brief_title": "The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Neuropsychological (NP) impairments more severe than described in the Inclusion\n             Criteria.\n\n          -  Evidence of nervous system dysfunction being caused by factors other than HIV\n             infection, including history of head trauma, multiple sclerosis, epilepsy, or\n             presence of concurrent central nervous system (CNS) infections or neoplasms, e.g.,\n             toxoplasmosis, primary or metastatic CNS lymphoma, progressive multifocal\n             leukoencephalopathy, cryptococcal or other fungal meningitis, and CNS tuberculous\n             infections.\n\n          -  Lymphoma or other tumor requiring cytotoxic chemotherapy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other antiretroviral agents.\n\n        Patients with the following are excluded:\n\n          -  AIDS or advanced ARC.\n\n          -  Neuropsychological (NP) impairments more severe than described above; i.e., defective\n             performance on NP test battery in 3 or more NP areas on the NP screening battery at 2\n             standard deviations below the mean.\n\n          -  Evidence of nervous system dysfunction being caused by factors other than HIV\n             infection, including history of head trauma, multiple sclerosis, epilepsy, or\n             presence of concurrent central nervous system (CNS) metastatic CNS lymphoma,\n             progressive multifocal leukoencephalopathy, cryptococcal or other fungal meningitis,\n             and CNS tuberculous infections.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents including zidovudine (AZT).\n\n        Prior Treatment:\n\n        Excluded within 3 months of study entry:\n\n          -  Blood transfusion.\n\n        Impaired performance on a defined neuropsychological test battery.\n\n          -  Asymptomatic HIV infection.\n\n          -  Persistent generalized lymphadenopathy (PGL).\n\n          -  Early AIDS related complex (ARC).\n\n          -  Seropositive for human immunodeficiency virus (HIV) demonstrated by positive ELISA\n             test and confirmed by Western blot with no or minimal symptomatology or HIV\n             infection.\n\n          -  Ability to give informed consent or a person with durable power of attorney who can\n             give informed consent.\n\n          -  Willingness to be followed by the originating medical center for 1 year.\n\n        History of drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002288", 
            "org_study_id": "014K", 
            "secondary_id": "23"
        }, 
        "intervention": {
            "intervention_name": "Zidovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Neuropsychological Tests", 
            "AIDS-Related Complex", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Research Triangle Park", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27709"
                }, 
                "name": "Glaxo Wellcome Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety and Efficacy of Retrovir in HIV Infected Patients Having Neuropsychological Impairments", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002288"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1995"
    }, 
    "geocoordinates": {
        "Glaxo Wellcome Inc": "35.902 -78.867"
    }
}